— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years — — JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of…
1 Followers, 5 Following, 2 Posts – See Instagram photos and videos from Sandeep Gautam (@gautamsandmd)
Hypertension is a global health problem with an estimated prevalence of 32% worldwide and increasing.1 In fact, hypertension is the most common modifiable risk factor…
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
New data from US centers suggest some overtesting in patients without chest pain, and undertesting in those who do.
We’re thrilled to announce Season 2 of The Digital Healthcare Experience! Setting the bar high with Dr. Ami Bhatt, Chief Innovation Officer at the American…
IMMUNOLOGY POSTDOC OPENING! Overview: We are seeking talented and enthusiastic postdoctoral scholars who have completed PhD or MD/PhD training, to join our lab focused on…
An early pioneer in the interventional community, Hildner advocated for sharing experiences to improve patient outcomes.
January 29, 2025—Penumbra announced that it has launched the Element vascular access system, a laser-cut hypotube sheath designed for treating v
